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Background and Objectives
Multiple myeloma (MM) is a malignant plasma cell neoplasia in which genetic stud-
ies have shown that genomic changes may affect almost all chromosomes, as shown
by fluorescence in situ hybridization (FISH) and comparative genomic hybridization
(CGH). Our objective was the genomic characterization of CD 138 positive primary MM
samples by means of a high resolution array CGH platform.
Design and Methods
For the first time, a high resolution array CGH with more than 40,000 probes, has
been used to analyze 26 primary MM samples after the enrichment of CD138-posi-
tive plasma cells.
Results
This approach identified copy number imbalances in all cases. Bioinformatics strate-
gies were optimized to perform data analysis allowing the segregation of hyperdiploid
and non-hyperdiploid cases by array CGH. Additional analysis showed that structural
chromosome rearrangements were more frequently seen in hyperdiploid cases. We
also identified the same Xq21 duplication in nearly 20% of the cases, which originat-
ed through unbalanced chromosome translocations. High level amplifications and
homozygous deletions were recurrently observed in our series and involved genes
with meaningful function in cancer biology. 
Interpretation and Conclusions
High resolution array CGH allowed us to identify copy number changes in 100% of the
primary MM samples. We segregated different MM subgroups based on their genom-
ic profiles which made it possible to identify homozygous deletions and amplifications
of great genetic relevance in MM.
Key words: multiple myeloma, arrayCGH, hyperdiploid, amplification,
homozygous deletion.
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ABSTRACT
Multiple myeloma (MM) is an incurable malignantplasma cell (PC) neoplasia characterized by theaccumulation of malignant plasma cells in the
bone marrow. There is a wide variability in clinical fea-
tures, responses to treatment, and survival times among
patients.1 Chromosome aberrations, present in virtually all
patients with MM2 include chromosome translocations
involving the IG loci and/or copy number changes of par-
tial or whole chromosomes.3 Two major genetic subtypes
of MM have been defined: the hyperdiploid variant (H-
MM), associated with multiple chromosome trisomies, and
the non-hyperdiploid variant (NH-MM) with a high preva-
lence of IGH translocations.4 This classification seems to
have relevance in prognosis since, recently, H-MM has
been associated with a better survival and a similar
response rate to treatment when compared to NH-MM.5
Chromosome-based comparative genomic hybridiza-
tion (CGH) has shown that DNA copy number variations
(CNV) in MM may affect almost all chromosomes.6-8 We
recently found, by array-based CGH (array CGH) CNV
that resulted in the overexpression of genes included in
amplified chromosomal regions.9 Here, we characterized
CNV in a panel of CD138-enriched primary MM samples
with high density array CGH. 
Design and Methods
Patients and molecular cytogenetics 
DNA from CD138+ cells, isolated from the bone mar-
row of 26 cases of MM at diagnosis, by means of mag-
netic cell sorting (Miltenyi Biotec, Aubum, CA, USA),
was studied. DNA was extracted using DNeasy tissue
kits (Qiagen, Germantown, MD, USA). All samples were
enriched to more than 70% plasma cells (median 95%)
(Supplementary Table 1). The median age of the patients
from whom the sampes were obtained was 67.5 years
(range: 34-85). There were 16 men and 10 women in our
series. Most patients (22/26) were homogenously treated
with the GEMM2000 protocol designed by the Spanish
GEM-PETHEMA group (Table 1). All samples were col-
lected after proper informed consent. All samples were
cytogenetically characterized: 85% showed a normal
karyotype. We screened our series by fluorescence in situ
hybridization (FISH) with IGH (Vysis, Downers Grove,
IL, USA) and IGL10 break-apart probes. Nine samples
(34.6%) showed IGH rearrangements and two (7.7%)
had IGL rearrangements.
Reference genomic DNA
Genomic DNA was obtained from peripheral blood of
ten healthy female donors. DNA was extracted using a
standard saline precipitation method and was purified by
phenol-chloroform extraction using Light Phase-Lock Gel
tubes (Eppendorf AG, Hamburg, Germany). The same
amounts of each donor DNA were mixed in a female
DNA pool for use as reference DNA in all hybridizations.
Array CGH assays
Human Genome CGH 44k microarrays (Agilent
Technologies, Palo Alto, CA, USA) were used in this study.
This platform consists of approximately 44000 60-mer
oligonucleotide probes that span the human genome with
an average resolution below 50 Kb. The platform has gene
focused coverage in order to ensure adequate coverage in
most commonly studied genomic regions. Array CGH
assays were performed as previously described11 with
minor modifications. The DNA pool from ten helathy
females was used as the reference DNA for all hybridiza-
tions. Slides were scanned using an Agilent 2565AA DNA
Microarray Scanner (Agilent Technologies). Raw data can
be freely accessed via our ftp server at www.cnio.es.
Images and data analysis
Microarray images were transformed to fluorescence
intensities using Feature Extraction Software, version 8.1
(Agilent Technologies). Data were analyzed using Agilent
CGH Analytics 3.2.25 software. Quality criteria were a
derivative log ratio (DLR) spread lower than 0.3 log units
and a signal to noise ratio for each channel greater than 30.
DLR spread metrics estimates the log ratio noise by calcu-
lating the spread of log ratio differences between consecu-
tive probes along all chromosomes. In order to establish
gained and lost regions, a 500 Kb weighted moving-aver-
age window and a ζ-score threshold of±2.5 were used. ζ-
score values were obtained for each probe and were cate-
gorized into gains and losses. Using this threshold, high
level amplifications were defined as consecutive clones,
spanning a region, which showed a log10 ratio higher than
0.3 (more than five copies) within a gained region and
homozygous deletions as consecutive clones with a log10
ratio lower than -1 (no copies) and detected as losses by ζ
–score. Those aberrant regions that did not reach these cut
off values were considered low copy gains or single losses.
For the subsequent analyses, regions of gains and losses
were established. A region is defined as a group of at least
three consecutive probes that are simultaneously and sim-
ilarly changed. 
Aberrations were categorized as numerical and structur-
al changes. The latter type was divided into changes
greater than 3Mb (>3Mb) and those less than 3Mb (<3Mb)
regarding high resolution conventional CGH resolution
(detailed data are provided in Supplementary Table 3).
Identification of H-MM and NH-MM 
H-MM and NH-MM were easily classified in our series
by array CGH. Based on the array CGH profile a copy
number score (CNS) value was assigned to each chromo-
some. When there was not a whole chromosome gain or
loss, a CNS value of 2 was assigned, when an entire chro-
mosome gain occurred, a CNS of 3 was assigned and,
finally, when a loss occurred the CNS was equal to 1. The
sum of CNS values of each case was calculated and if the
value was from 48 to 74 the case was classified as H-MM;
when a different CNS was obtained, it was considered
C. Largo et al.  
| 796 | haematologica/the hematology journal | 2007; 92(06)
Array CGH in primary MM samples
haematologica/the hematology journal | 2007; 92(06) | 797 |
Table 1. General features of the multiple myeloma samples included in the study. 
FISH Array CGH
Case M/F Treatment Response Karyotype Ig t Ploidy 13q- 1q+ dup
(age) Xq
1 M(78) GEMM2000 No 46,XY/45,X,-Y − H − − −
2 M(66) GEMM2000 No 46,XY − H − − +
3 M(39) GEMM2000 Yes 46,XY IGH+ NH − − −
4 M(61) GEMM2000 Yes 46,XY − NH − + +
5 F(67) NT x 46,XX − NH − − −
6 M (71) GEMM2000 No 46,XY IGH+ NH + + −
7 M (73) GEMM2000 No 46,XY IGH+ NH − − −
8 F (75) NT x 46,XX − NH + − −
9 M(68) GEMM2000 NO 57,XY<3n>, IGL+ H − + −
-1,der(6)t(1q;6q)x2,-8,-13,-14,-16,-17,-18,-20
10 M(70) GEMM2000 Yes 46,XY − H + − −
11 M(72) GEMM2000 Yes 46,XY IGL+ H + + +
12 M(58) GEMM2000 Yes 46,XY − NH + + −
13 F(34) GEMM2000 Yes NA IGH+ NH + − −
14 F(67) GEMM2000 Yes 46,XX IGH+ NH − − −
15 M(57) GEMM2000 Yes 46,XY IGH+ NH + − −
16 M(67) Thalidomide Yes 46,XY − NH − − −
vs placebo
17 F (52) GEMM2000 Yes 46,XX, − H − + −
inv(9)(q11q13) 
[100%]
18 M(85) NT x 46,XY − H − − −
19 F (62) GEMM2000 Yes 46,XX − H + + +
20 M (59) GEMM2000 No 46,XY,der(1p),+3,+5, − H + + +
der(8p),der(9p),-
13,add(13p),
add(14)(q32), +15,er(16q),
der(20q),+mar [100%]
21 F (66) GEMM2000 Yes 46,XX [67%]50,XX, − H − − −
add(1)(p36),
der(3q), t(3;3)(q?;q?),
+7,add(12)(p13),
der(14q),+mar [33%]
22 F(71) GEMM2000 Yes 46,XX IGH+ NH + − −
23 M(73) GEMM2000 Yes 46,XY − H − − −
24 M(81) GEMM2000 Yes 46,XY IGH+ H − − −
25 F(74) GEMM2000 Yes NA IGH+ NH − + −
26 F(54) GEMM2000 No 45,X,-X[87%] − H − + −
51,XX,der(1)(p?),
+3,+5,+7,+8,-9,+11,der(14)(q?),
add(16)(p?),+18 [13%]
Besides clinical features, Ig translocation status (Ig t determined by FISH) and known genetic features (determined by array CGH) are shown. M: male; F: female;
NT: not treated.
NH-MM. Ploidy status was further confirmed by a stan-
dard FISH assay based on centromeric probes (Vysis,
Downers Grove, IL, USA).
Definition of smallest overlapping regions of
imbalance (SORI) 
Genomic aberration region data were used to obtain the
SORI. Each SORI represented the most recurrent region of
imbalance whose limits were defined by the minimum
number of clones with the highest percentage of recur-
rence.12 SORI were defined independently for gains and
losses. They were evaluated to define regions targeted by
overlapping events in two or more samples. SORI limits
were defined by the clones at the boundaries of the gained
or lost region of the case showing the smallest unbalanced
region. After SORI delimitation the presence or absence of
belonging aberration was assigned to each sample
(0=absence, 1=presence).
Bioinformatics and statistical analysis
GEPAS Suite software (http://gepas.bioinfo.cipf.es/) was
used for unsupervised clustering, supervised analysis and
gene annotation. A region was considered as statistically
significant if the adjusted p value was below 0.05. For sta-
tistical comparison of the difference in the number of copy
number changes in different groups, the U Mann-Whitney
test was used with the SPSS v 13.0 package.
FISH and spectral karyotyping (SKY) analysis
FISH assays were carried out as described elsewhere.13 In
order to identify whether there were any translocations
involving the immunoglobulin (Ig) heavy and light chain
loci, FISH assays were conducted with LSI IGH Dual Color
Break Apart probe and IGL break apart probe.10 A non-
commercial probe was used for the analysis of Xq21-qter
duplication (Supplementary Table 3). Total Chromosome
DNA X Probe (Qbiogene, Carlsbad, CA, USA) was used in
combination with LSI IGH Dual Color Break Apart probe
(Vysis), in order to study the involvement of IGH in Xq21
translocation. The probes used for the validation of ampli-
fication and homozygous deletions are described in sup-
plementary Table 3.
SKY was carried out as previously described.13,14 At least
five metaphases were analyzed for each case.
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Table 2. Description of 68 recurrent SORI identified in the MM samples.
Gains Losses
Chr Region Start Size (Mb) % Chr Region Start Size (Mb) %
1 1q 142902432 102.520 38 1 1p36.32 1536308 5.000 8
3 3pter1 224727 3.337 35 1 1p36.12 23265113 0.604 8
3 3q11-q221 108062308 32.496 38 1 1p333 50669458 3.014 8
3 3q26-qter1 197698952 1.593 42 1 1p31.13 80821425 2.856 12
5 5p-q13.21 148243 73.955 38 1 1p21.3-p31.1 84171854 12.042 12
5 5q21.11q-ter1 96057266 84.560 38 1 1p12-p21.1 103799708 14.591 15
6 6p22.1-25.2 352463 26.129 23 3 3p24.3 24930353 0.880 12
6 6q12 64228424 3.086 15 4 4p16.23 1661893 0.184 12
6 6q12 69403244 1.154 15 4 4p15.333 13019621 0.285 12
7 7p21.11,2 5637996 0.178 35 4 4p15.31-p15.13 16751089 14.070 8
7 7p21.11,2 11853187 0.515 35 4 4p133 44691513 1.538 8
7 7p21.11,2 16776548 0.337 31 4 4q13.2-q22.1 66059589 26.058 8
7 7p14.11,2 36074495 0.333 35 6 6q23.2 136920041 0.341 12
7 7q1,2 61960303 96.628 27 6 6q263 160608251 0.522 15
8 8q23.3-q24.21 117725989 8.097 12 7 7p22 1263119 0.093 8
8 8q24.213 128548643 0.407 15 8 8p12-p22 13991907 13.105 27
9 9q22.2 89830592 1.734 42 8 8p11.22 37847079 0.527 19
9 9q34.21 132972692 0.043 50 8 8q23.1 107376988 0.545 8
11 11q13.2-q13.4 68821295 7.553 31 9 9p21.3 21067574 0.786 8
11 11q23.2-qte1 114350685 19.601 35 11 11q22.1 100828925 1.492 8
15 151 19109124 81.060 42 12 12p13.32 3509030 0.820 8
16 16q22.2 69322931 0.553 8 12 12p12.1 21152676 0.400 12
17 17p13.2 3632698 1.334 12 12 12q21.33 86882565 0.906 8
17 17p11 16763408 0.663 15 13 13q12.12 19140499 0.376 35
17 17q21.32 41458670 0.242 23 13 13q12-q21 45637710 20.455 38
18 18 170229 75.913 15 14 14q13.2-q21.3 30209271 16.915 12
19 19p13.12-pter1 232080 17.754 65 14 14q24.2 68763265 14.399 15
19 19q13 34522544 1.330 50 14 14q32.32 101569155 1.268 15
19 19q13.21 42921103 0.673 50 16 16p13.2 3646249 0.601 8
20 20q11.22 31714033 0.387 8 16 16p13.12 13923497 0.026 23
21 21q21.1 15295891 4.694 12 16 16q24.23 83644296 1.600 23
X Xq21.333-q25 97661774 26.092 19 17 17p13.2-p12 7054388 9.209 15
X Xq25-qter 126030916 28.374 19 20 20q12 37664253 0.577 8
22 22q11.22 21004565 0.344 19
22 22q12.1 22555378 5.501 23
1SORI that were significantly (adjusted p-value <0.05) more frequent in the H-MM group than in the NH-MM group. 2Statistically significant SORI identified in one
of the H-MM groups. 3SORI present in one of the NH-MM groups, but not statistically significant.
Results
A high number of genomic aberrations were found in MM
The presence of DNA copy number changes in 26 pri-
mary MM samples was analyzed by high resolution array
CGH. Most of the samples had a normal karyotype at
diagnosis (Table 1); however, genomic copy number
analysis, performed on CD138+ cells, allowed the identifi-
cation of CNV in 100% of the cases. A total of 270 copy
number changes (ranging from 2 to 26) were found; 145
were copy number gains and 125 were losses. The medi-
an size of the aberration was 36 Mb (range, 0.026 Mb to
199 Mb). Gains most frequently involved chromosomes
19 (65%), 9 (42%), 15 (42%), 5 (38%), 3 (38%), 7 (35%)
and 1q (38%), and losses in 13q (38%), 8p (35%), 16p
(31%), 22q (31%) and 1p (27%). The most frequent aber-
rations were structural rearrangements involving chromo-
some segments (41.5% of the changes), followed by
whole chromosome gains and losses (31.1%). There are
two major genetic categories of MM: H-MM with 48 to 74
chromosomes due to specific chromosome gains and NH-
MM without this genotype. Fifty percent of our cases
were H-MM, the other fifty percent  were NH-MM, ini-
tially assessed by array CGH and confirmed by conven-
tional FISH (Table 1). Furthermore, unsupervised cluster-
ing, carried out with the most frequent aberrations found
in our series, segregated two groups belonging to H-MM
and NH-MM (Supplementary Figure 1). When H-MM and
NH-MM cases were compared, we found that numerical
changes were significantly more frequent in H-MM sam-
ples (p<0.001) due to a higher frequency of whole chromo-
some gains (p<0.001). However, monosomies seemed to
be more frequent in the NH-MM group (p=0.076). As far
as structural aberrations, we found that gains >3Mb were
significantly more frequent (p=0.037) in H-MM cases
(Supplementary Table 3). Other types of changes were
equally distributed in both groups.
Clustering analysis identified two different H-MM
subgroups
In order to obtain a reliable picture of common aberra-
tions present in this series, we defined the SORI for gains
and losses. Sixty-eight SORI were identified: 33 gains and
35 losses (Table 2). The most frequent gained SORI was
19p13.12-pter (65%) followed by 9q34, 19q13 and
19q13.2 (50%) and the most frequent losses were in
13q12-q21 (38%), 13q12.12 (35%), 8p12-p22 (27%) and
16p13.12 (23%). The median size was 1.5 Mb ranging
from 0.026 Mb (a few genes) to 102 Mb (whole chromo-
somes). Deletion at 16p13.12, present in 23% of the cases,
affected only ERCC4, a modifier gene reported to be
Array CGH in primary MM samples
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Table 3. Description of amplifications and homozygous deletions identified in MM. 
Amplifications
Chr Region Start Size (Mb) Cases with HLA % cases G Genes in the region
6 6q12 64228424 3.086 26 11.5 PTP4A1, PHF3, LOC389405, EGFL11
6 6q12 69403244 1.154 26 11.5 BAI3, C6orf209
9 9q22.2 89830592 1.734 4 30.8 LOC340515, DIRAS2, SYK, BF510209, AUH, NFIL3, ROR2
9 9q34.2 132972692 0.043 20, 191 42.3 CEL, RALGDS
14 14q21.1 44463153 0.372 14 0 BTBD5,KIAA0423, PRPF39, FKBP3, C14orf106
16 16q22.2 69441287 0.312 4 3.8 HYDIN
17 17p13.2 3632698 1.334 26 7.7 HSA277841, CAMKK1, P2RX1, ATP2A3, ZZEF1, ANKFY1, UBE2G1,
MYBBP1A, FLJ90165, ALOX15, PELP1, ARRB2, CXCL16, ZMYND15,
TM4SF5, LOC284013, PSMB6, PLD2, MINK1, CHRNE, GP1BA,
SLC25A11, RNF167, PFN1, ENO3, SPAG7, CAMTA2, INCA1,
KIF1C, GPR172B, FLJ30726, ZNF232
17 17p11 15589242 1.837 23, 261 7.7 FLJ40244, ADORA2B, TTC19, NCOR1, PIGL, PRR6, TRPV2, FLJ35696,
ZNF287, ZNF624, FLJ36492, TNFRSF13B, M-RIP, LOC201164, FLCN,
COPS3, NT5M, MED9, RASD1, PEMT
19 19q13 34522544 1.299 4 46.2 LOC284395, POP4, PLEKHF1, C19orf12, CCNE1, C19orf2, ZNF536
Homozygous deletions
Chr Region Start Size (Mb) Cases with HD % Hem.D. Genes in the region
6 6q26.2 137061308 0.199 4 7.7 MAP3K5, PEX7
11 11q22.1 100828925 1.491 2 3.8 TRPC6, ANGPTL5, KIAA1377, YAP1, BIRC3, BIRC2, PORIMIN, MMP7,
MMP20, MMP27, MMP8, MMP10, MMP1, MMP3, MMP12, MMP13
13 13q12 19140499 0.376 20, 152 26.9 HSMPP8, PSPC1, ZNF237, ZNF198
22 22q11.22 20994020 0.354 12 15.4 IGLC2, SUHW2, SUHW1, PRAME
X Xq21.31-21.33 86728457 10.933 4 0 PABPC5, NAP1L3, FLJ37659, DIAPH2, CPXCR1, KLHL4, PCDH11X
X Xq25 123753696 2.090 4 0 WDR40B
1When recurrent amplification was revealed, the smallest overlapping region of amplification is described. 2Case 23634 shows two consecutive clones homozygously delet-
ed covering the ZNF198 gene locus. HLA: high level amplification; G: gain; HD: homozygous deletion; Hem. D: hemizygous deletion.
involved in breast cancer.15 Unsupervised and supervised
clustering analyses were performed using SORI as vari-
ables (Figure 1A). Unsupervised analysis was able to segre-
gate H-MM from NH-MM, and after a supervised analy-
sis, gained regions in chromosomes 15, 5, 19, 3, 9, 7 and
11q were found to be significantly (adjusted p-value <0.05)
more frequent in the H-MM group. In the unsupervised
analysis, our H-MM cases appeared to be distributed in
two subgroups that statistically differed (adjusted p-
value=0.03, Fisher’s exact test) according to the presence of
gains in chromosome 7. Similarly, the unsupervised clus-
tering analysis segregated two different subgroups within
the NH-MM cases. One of the clusters, formed of only
two cases, was characterized by the presence of a high
number of CNV, such as gains in 8q24.21 (C-MYC) and
absence of IGH translocations. 
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Figure 1. Unsupervised clustering
results, ideograms showing array CGH
profiles and SKY images. A. Unsuper-
vised clustering revealing the molecular
heterogeneity in primary MM samples.
Unsupervised clustering was carried out
with 68 SORI identified. The analysis
segregated the hyperdiploid cases from
the non-hyperdiploid ones. The H-MM
group could be divided in two sub-
groups. Statistically significant SORI
that separated H-MM and NH-MM are
highlighted with a blue key, and chromo-
some 13 deletion and 1q duplication
are marked with gray arrows. B. Red
and blue lines depict the 500 Kb mov-
ing average CGH ratio. Bars on the left
indicate losses and bars on the right
gains (ζ-score threshold of 2). Left
ideogram. Chromosomes X, 13 and 21
array CGH plots and SKY picture of case
#20. The sample was from a male, the
control DNA was a pool of female DNA.
Xq duplication is depicted as a normal
pattern after a loss. Chromosome 21 tri-
somy and chromosome 13 homozygous
deletions are also shown. SKY assays
confirmed the array CGH results and
revealed that the Xq21 duplicated frag-
ment and remaining chromosome 13
were involved in different transloca-
tions. Right ideogram. Array CGH pro-
files of chromosome X and 14 showing
Xq21 duplication and chromosome 14
breakpoint in L363. SKY analysis
showed that the duplicated fragment
was involved in a translocation with
chromosome 14. 
A
B
X X
13 14
21
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New genomic aberrations in MM
High level amplifications and homozygous deletions
represented 7% of the observed CNV. They appeared in
H-MM and NH-MM, but, in general, clustered in cases
that accumulated a high number of genomic aberrations.
Nine high level amplifcations were found and most of
these regions were also gained (Table 3) in other cases
from our series. Among the genes contained in all the
amplified regions, 31% are involved in signal transduction
(GO:0007165), such as DIRAS2, ADORA2B, TNFRSF13B,
RALGDS, CCNE1 and SYK. Six homozygous deletions
were observed (Table 3). Reinforcing the putative patho-
genic role of this finding, these regions also showed up as
single copy losses in several additional samples of our
series. Of interest, we observed a 376 Kb homozygous
deletions  in chromosome 13, where four genes (HSMPP8,
PSPC1, ZNF237, ZNF198) are located (Table 2). This dele-
tion was observed in two cases (#15 and 20). Case #20
showed a single copy of chromosome 13 that was
involved in a translocation with chromosome 14 (Figure
1). Case #15 showed a homozygous deletions  that includ-
ed two consecutive clones involving only ZNF198. In gen-
eral, the genes are involved in cellular physiological
processes (GO:0050875), although some of them are more
specifically involved in cell death (GO:0008219) and signal
transduction (GO:0007165), such as BIRC2, BIRC3 and
MAP3K5; and others are metalloendopeptidases
(GO:0008237) such as MMP8, MMP10, MMP1 and
MMP13. These high level amplifications and homozygous
deletions were validated by FISH assays using BAC clones
covering genes in lost or gained regions (Supplementary
Figure 2).
A novel duplication on Xq21.33 was identified in five
out of the 26 primary cases and in the MM cell line L363.
FISH studies allowed the mapping of the duplication
breakpoints that clustered around a 10 Mb region in
Xq21.33 (from nearly 86122579bp to 98277428 bp). SKY
analysis (Figure 1) demonstrated that duplications were
the unbalanced outcome of translocations with break-
points at Xq21: in L363 involving chromosome 14q,
t(X;14)(q21.33; q31.1); and in case #20 involving chromo-
some 21; t(X;21)(q21.33;q22.3). The breakpoint in chro-
mosome 14 was revealed out by the array CGH profile
and we confirmed that IGH was not involved by using a
combination of a chromosome X painting probe
(Qbiogene) and the LSI IGH Dual Color Break Apart probe
(Vysis) in the same hybridization (Supplementary Figure 2). 
Discussion
Multiple myeloma is an incurable malignant plasma cell
neoplasia characterized by the accumulation of malignant
plasma cells in the bone marrow. Genetically, MM is
defined by a large and variable number of genetic and
chromosome rearrangements. In general, two major genet-
ic subtypes of MM have been defined: the hyperdiploid
variant associated with multiple chromosome trisomies
and the non-hyperdiploid variant with a high prevalence
of IGH translocations.5 While the biology of MM bearing
IGH translocations has been extensively studied,16 little is
known about the impact of genomic gains and losses in
the pathogenesis of MM . In this regard, candidate genes,
overexpressed in amplified chromosomal regions in MM
cells lines have recently been proposed.9 These events
have been described in other types of cancer and have
been used as therapeutic targets.
In this study, an array CGH platform was used for the
analysis of copy number imbalances in CD138+ plasma
cells. Although, as expected, most of the samples showed
an unaltered karyotype at diagnosis, we found CNV in all
of them. Observed frequencies of CNV, losses of chromo-
some 13q and duplications of chromosome 1q, and Ig
genes translocations, were concordant with those in previ-
ous studies.6,7,9,12,17 Array CGH enabled efficient segregation
of the series into H-MM and NH-MM cases; half of the
cases were H-MM and half NH-MM. The presence of IGH
translocations was associated with NH-MM; among the
H-MM cases, only one showed IGH translocations and
two IGL translocations. It has been suggested that translo-
cations present in H-MM are secondary events.5,17
Array CGH provides a level of resolution that over-
comes the limits of chromosome-based CGH which is, in
the best conditions, near 3 Mb. Due to the high resolution
of the platform (44K) we identified several aberrations
smaller than this limit, distributed in both H-MM and NH-
MM cases, which had not been previously described. We
delimited several SORI, offering a reliable picture of the
aberrations occurring in MM.12 Apart from segregating the
two major genetic categories of MM, the unsupervised
clustering based on the SORI aberration (Figure 1A) iden-
tified two H-MM subgroups, one of which was associated
with chromosome 7 gains. Gains in 7q have been
described in Burkitt´s lymphoma,18 a combination in
which they were associated with a poor outcome.
The approach used also allowed the identification of
novel genomic markers and the definition of high level
amplifications and homozygous deletions. Nine high
level amplifications were identified. Some of them, such
as 9q22.2, 19q13 and 16q22.2, had not been previously
described in MM, but may harbor candidate oncogenes,
as we have demonstrated in mantle cell lymphoma, in
which we observed primary samples showing amplifica-
tion and overexpression of SYK,19 or CCNE1, in 19q13,
which has been shown to be amplified and over-
expressed in endometrial and bladder neoplasia.20,21 Most
of the homozygous deletions we found had not been
previously described in MM. Reinforcing the putative
pathogenic role of this finding, these regions also showed
up as single copy losses in several additional samples of
our series. As regards homozygous deletion in chromo-
some 13, ZNF198 seems to be a good candidate for the
target of the deletion because, besides the deletion
described in case #20, in case #15, the homozygous dele-
Array CGH in primary MM samples
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tion covered only the ZNF198 gene. Furthermore, candi-
date genes such as PORIMIN, YAP1 and MMP8, which
are located in the  homozygous deletion that we found at
11q22.2, were reported to be deleted and down regulat-
ed in a previous study. Five cases showed duplication on
Xq21.33. Although some CGH studies have reported
data on Xq aberrations,22,23 we provide here the first
description of the frequency and genetic origin of this
marker in MM.  In summary, our study represents the
analysis of CNV in MM at the highest level of resolution
ever reported. Our work includes some data confirming
results obtained with other technological approaches,
and provides a complete genomic characterization of the
two genetic categories of MM. Additionally, we have
demonstrated for the first time that extreme genomic
aberrations, such as high level amplifications and
homozygous deletions, are frequent events in MM. We
believe that these data warrant further investigation to
gain a deeper insight into the role of genomic instability
in MM and its potential use for therapeutic purposes.
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